fig1

Therapeutics to harness the immune microenvironment in multiple myeloma

Figure 1. Direct and indirect effects of FDA-approved and developmental agents on MM cells and their interaction with other cell types within the tumor microenvironment. CAR: Chimeric antigen receptor.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/